Isotretinoin Treatment Associated With Insomnia in Young Patients With Acne
Treatment of acne with isotretinoin was associated with significantly higher risk for insomnia, a possible early indicator of vulnerability to serious psychiatric disorders.
Acne
Changes in Diet Can Improve Acne
Dietary interventions cannot only improve acne but have the opportunity to improve overall health.
Arazlo Lotion Now Available for Acne Vulgaris
Arazlo™ (tazarotene; Bausch Health Companies) Lotion 0.045% is now available for the topical treatment of acne vulgaris in patients aged ≥9 years.
Vitamin B-12 Intake: An Underestimated Cause of Acneiform Eruptions?
Intramuscular and oral vitamin B12 may represent an underappreciated cause of acneiform eruption in some patients.
IBS Frequency Higher in Patients With Acne
A novel study examines the relationship between acne vulgaris and irritable bowel syndrome.
Resistance Data Added to Labeling for Acne Drug Seysara
The FDA has approved updated labeling for Seysara® (sarecycline; Almirall LLC) to include information stating that Propionibacterium acnes (recently renamed Cutibacterium acnes) strains displayed a low propensity for the development of resistance to sarecycline.
Once-Daily Tazarotene Lotion Promising Option for the Treatment of Acne
An evaluation of the safety and efficacy of a novel tazarotene topical for acne finds a possible new treatment option.
Could Isotretinoin Reduce the Risk for SARS-CoV-2 Infection?
Isotretinoin possesses a number of properties that might lower a patient’s risk for acquiring SARS-CoV-2.
International Guidelines for Treatment of Mild to Moderate Acne: An Overview
Common and alternative treatment options for mild to moderate acne, as noted by 3 widely distributed guidelines, are reviewed.
Laboratory Abnormalities Rarely Serious in Older Patients Receiving Oral Isotretinoin
Expanding recommendations for less frequent laboratory monitoring of patients with acne ≥35 years old prescribed isotretinoin without baseline laboratory abnormalities is now supported.
-
Loading...
-
Loading...
